Sugi Predict

Sugi Predict / Compounds / SCHEMBL19861696

SCHEMBL19861696

SCHEMBL19861696

CCCCCCCCc1cncs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXAS1 P24557 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KCNH2 Q12809 1/20 0.38
▸ TLR7 Q9NYK1 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ SLC6A3 Q01959 3/20 0.35
▸ CTSK P43235 1/20 0.34
▸ PTGS2 P35354 3/20 0.34
▸ ESR1 P03372 2/20 0.34
▸ ADRA2A P08913 2/20 0.34
▸ ADORA3 P0DMS8 2/20 0.34
▸ TACR2 P21452 2/20 0.34
▸ SLC6A2 P23975 2/20 0.34
▸ SLC6A4 P31645 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SHBG P04278 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16266833 1.00 TBXAS1 (0.39) TBXAS1TDP1L3MBTL1KCNH2TLR7
SCHEMBL3429691 0.98 TDP1 (0.40) TBXAS1TDP1L3MBTL1KCNH2TLR7
SCHEMBL1527343 0.92 — —
SCHEMBL6032061 0.83 — —
SCHEMBL2095928 0.80 TBXAS1 (0.39) TBXAS1TDP1TLR7SLC6A3SLC6A2
SCHEMBL2095925 0.80 SLC6A3 (0.37) TDP1SLC6A3SLC6A2SLC6A4LMNA
SCHEMBL1291571 0.80 SLC6A3 (0.33) TDP1SLC6A3SLC6A2
SCHEMBL25488068 0.78 LMNA (0.38) SLC6A3CTSKSLC6A2LMNA
SCHEMBL18893462 0.78 LMNA (0.38) SLC6A3CTSKSLC6A2LMNA
SCHEMBL2095989 0.78 SLC6A3 (0.34) TDP1SLC6A3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-10-26 — — US disclosed
US-20210040083-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-02-11 — — US disclosed
US-10793563-B2 GCN2 inhibitors and uses thereof MERCK PATENT GMBH (DE) 2020-10-06 — — US disclosed
US-20190233411-A1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-08-01 — — US disclosed
US-20190048020-A1 DEUTERIUM-MODIFIED CFTR MODULATORS CONCERT PHARMACEUTICALS, INC. 2019-02-14 — — US disclosed
US-9891239-B2 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES, INC. (US) 2018-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233411-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR TBXAS1 3413/4885TDP1 2231/4885L3MBTL1 2553/4885
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 TBXAS1 1754/4885TDP1 557/4885L3MBTL1 68/4885
US-20210040083-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR TBXAS1 3413/4885TDP1 2231/4885L3MBTL1 2553/4885
US-20190048020-A1 DEUTERIUM-MODIFIED CFTR MODULATORS CFTR, PKD2, PKD1 TBXAS1 737/4885TDP1 3960/4885L3MBTL1 4133/4885
US-10793563-B2 GCN2 inhibitors and uses thereof EIF2AK4, GCN1, GCGR TBXAS1 3413/4885TDP1 2231/4885L3MBTL1 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.